Doctor smiling
Doctors analyzing x-Ray

Redefining the Potential of Immunotherapy

Dentritic
Cell Vaccines

Developed at the Texas Medical Center, DOC1021 represents a novel approach to fighting cancer that harnesses the body’s natural anti-viral immune response.

At the core of DOC1021 is Diakonos’ proprietary “double-loading” technique. This patented process tricks the body into perceiving cancer cells as virally infected cells, mirroring the natural detection and elimination process for viral infections.
Learn More
Hexagons

Powered by a

Groundbreaking
Discovery on the
Immune System

DOC1021 is based on a discovery on how dendritic cells are able to detect and respond to viral threats. Based on Diakonos’ research, it is now known that dendritic cells compare antigens presented on MHC Class 1 and 2.

When identical antigens are detected on both MHC Class 1 and 2, dendritic cells mobilize formidable CD8 CD161 T cells to destroy what the immune system believes are infected cells throughout the body.
Learn More About Our Research

Clinical Trials

Underway

Discover our treatment centers and find out which one is best for you.

Baylor College of MedicinePhase 1, NCT04157127

Pancreatic Adenocarcinoma

Baylor College of MedicinePhase 1, NCT04157127

Conducted in partnership with the Baylor College of Medicine, this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous Dendritic Cells (DCs) to Pancreatic Cancer patients as adjuvant therapy following completion of standard chemotherapy.
MD Anderson Cooper, UT Health Science Center<br /> Phase 1, NCT04552886

Glioblastoma

MD Anderson Cooper, UT Health Science Center
Phase 1, NCT04552886

Conducted in partnership with the MD Anderson Cooper Hospital, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Glioblastoma (GBM) after undergoing neurosurgical tumor resection, and in whom a neuropathological diagnosis has been established.
MD Anderson<br /> Phase 1, Pending

Sarcoma

MD Anderson
Phase 1, Pending

Conducted in partnership with the MD Anderson, this is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a Diakonos loaded Dendritic Cell Vaccine in nine to twenty-four adult patients diagnosed with Sarcoma after undergoing Standard of Care.